Abstract
Proton-pump inhibitors (PPIs) form the recognized cornerstone of therapy for gastroesophageal reflux disease (GERD). Sustained maintenance of pH higher than 4 has correlated with prompt resolution of GERD symptoms and high rates of esophagitis healing. To date, none of the newer PPIs -- lansoprazole, rabeprazole, or pantoprazole -- have proven significantly better than omeprazole at maintaining pH higher than 4, when clinically relevant endpoints were used. Compared with omeprazole, its S-isomer (esomeprazole) …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
